ILiAD

Funding reported, Series B, last update 6 months ago

Pharma biotech · Headquarters Paris, France

Everything we hold on ILiAD, newest first. Every line links to the filing or report it came from.

This profile is thin because we hold one source document on ILiAD so far, not because nothing else has happened there. We only publish what we have read on a primary source and can link to. So a profile fills up as filings and reports come in, and we never seed it from an estimate. We keep profiles at this stage out of our sitemap and mark them noindex until they carry enough to be worth a search result of their own.

1. 2026-02-11
   Headcount Not Stated Growing and expanding

   ILiAD secures $115m Series B to propel pertussis vax

   ILiAD raised $115M in Series B funding to advance its pertussis vaccine, a stage where biotech companies typically build out clinical and manufacturing teams. The announcement names no roles.

   Paris, France · $115M raised · News Report · bioxconomy.com · archived copy

The read-through on each line is our interpretation. The headline and figures come from the linked source. Data licensed CC BY 4.0. Back to the tracker